Dyadic International Inc revenue
Dyadic International Inc's revenue was $3.1m in fiscal 2025, down 11.6% on the year before. Since fiscal 2017 ($758,420) it has grown at a compound 19.2% a year. Over the last twelve months it was $3.8m.
Revenue history
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 758 | 1,295 | 1,681 | 1,602 | 2,404 | 2,930 | 2,899 | 3,495 | 3,090 | 3,802 |
| Growth on the year before | — | +70.8% | +29.8% | −4.7% | +50.1% | +21.9% | −1.1% | +20.6% | −11.6% | — |
| Gross profit | 78 | 268 | 221 | 177 | 459 | 807 | 923 | 2,301 | 770 | 618 |
| Gross margin | 10.3% | 20.7% | 13.2% | 11.0% | 19.1% | 27.5% | 31.8% | 65.8% | 24.9% | 16.2% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Grant | $1.9M | 60.1% | — |
| Research and Development | $967,311 | 31.3% | ▼ 39.7% |
| Licenses | $265,000 | 8.6% | ▼ 86.0% |
From Dyadic International Inc's 10-K filed March 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Dyadic International Inc | $3.8m | -8.0% | 3.4% |
| DBV Technologies S.a. | $3.8m | -31.6% | -11.6% |
| Aligos Therapeutics, Inc. | $3.7m | 19.4% | -5.5% |
| Camp4 Therapeutics Corp | $4.2m | 40.2% | — |
| Curis Inc | $4.3m | -62.2% | -25.0% |
| Xenetic Biosciences, Inc. | $3.3m | 33.3% | 14.7% |
Compare with peers
- DBV Technologies S.a. revenue
- Aligos Therapeutics, Inc. revenue
- Camp4 Therapeutics Corp revenue
- Curis Inc revenue
- Xenetic Biosciences, Inc. revenue
Head to head: DBVT vs DYAIALGS vs DYAICAMP vs DYAIDYAI vs XBIO
More: Biotechnology stocks compared, Health Care sector, rankings of US companies